Department of Immunology
The Department of Immunology at the University of Pittsburgh has a long tradition of excellence in immunology research and training. Students and postdoctoral fellows walk through hallways that are pictorial reminders of the days when Jonas Salk worked here on discovering the polio vaccine, or when Niels Jerne chaired the Microbiology Department and worked on perfecting the Jerne plaque assay for antibody producing cells.
Thomas E. Starzl Transplantation Institute
The Starzl Transplantation Institute (STI) is a multidisciplinary environment where basic and clinical researchers are building on a long history of pioneering discovery and clinical achievements. The basic research programs of the STI use invertebrates, rodents, and large animal models, as well as patient samples, to answer fundamental questions in Immunology, Cell Biology, Virology, and Pharmacology. We are seeking answers that will provide the solutions to transplantation's most challenging problems. In the tradition of our namesake, Thomas E. Starzl, MD, PhD, who established clinical liver transplantation and introduced the immunosuppressive drugs that revolutionized clinical transplantation, STI's clinical research programs seek to improve short and long-term graft and patient survival through innovation and translation of basic and pre-clinical discoveries. Presently, we are developing immunological monitoring strategies that will enable us to optimize immunosuppression and testing cutting-edge immunomodulatory approaches that will permit improvement in transplantation outcomes without increased burden of immunosuppression
UPMC Hillman Cancer Center
Founded in 1985, the UPMC Hillman Cancer Center is the only National Cancer Institute (NCI)-designated Comprehensive Cancer Center in western Pennsylvania. With nearly 400 research and clinical faculty members specializing in disciplines ranging from cancer prevention and early detection to novel therapeutic discovery, survivorship, and end of life care, UPMC Hillman Cancer Center maintains a broad strategic vision and comprehensive approach to understanding and defeating cancer. UPMC Hillman Cancer Center investigators are leaders in molecular and medical oncology and tumor immunology. At UPMC Hillman Cancer Center, basic researchers collaborate with clinician-scientists to rapidly advance the most promising laboratory studies into novel clinical trials, providing patients with early access to new and innovative treatments both at the Hillman Cancer Center and throughout the network of UPMC Cancer Center sites. Currently, patients have access to hundreds of clinical trials at UPMC Hillman Cancer Center.